Reported incidence and survival of fallopian tube carcinomas: A population-based analysis from the North American Association of central cancer registries

Britton Trabert, Sally B. Coburn, Andrea Mariani, Hannah P. Yang, Philip S. Rosenberg, Gretchen L. Gierach, Nicolas Wentzensen, Kathy A. Cronin, Mark E. Sherman

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Recognition that serous tubal intraepithelial carcinoma (STIC) may represent the first manifestation of many high-grade cancers that were once considered ovarian primary tumors has led to changes in diagnostic practices that could dramatically increase the reporting of tubal carcinomas in US population-based cancer registries. Further, increased detection of early-stage tubal carcinomas through increased recognition coupled with meticulous pathology processing protocols raises important unanswered questions about the clinical behavior of such lesions, which can only be answered using large data sets. However, rates of tubal carcinomas have not been recently analyzed. Accordingly, we analyzed population-based incidence and survival data for fallopian tube carcinoma in situ (CIS; an imperfect surrogate of STIC), tubal carcinomas, and for comparison, ovarian carcinomas, in the North American Association of Central Cancer Registries (NAACCR) registries. Methods: Total counts, standardized incidence rates, and stage-specific survival were computed using 30 NAACCR registries (1999-2012). Temporal incidence rate patterns were analyzed by joinpoint regression with estimates of annual percentage change (APC). All statistical tests were two-sided. Results: Fallopian tube CIS incidence rates were stable from 1999 to 2002, then increased from 2002 to 2012 (APC = 16.2%, 95% confidence interval [CI] = 10.9% to 21.7%, P <.001). Rates of early- and late-stage tubal carcinomas showed similar patterns, whereas high-grade serous ovarian carcinoma rates were relatively stable. Five-year cause-specific survival was 97.9% (95% CI=93.7% to 99.3%) for tubal CIS and 83.2% (95% CI=77.3% to 87.7%) for early-stage high-grade serous tubal carcinoma. Conclusions: Reporting of tubal CIS and tubal carcinoma have increased in recent years, likely reflecting changes in pathology processing of specimens and diagnosis. Developing standardized reporting for tubal neoplasms is needed to enable analysis of outcomes for these comparatively uncommon but increasingly recognized tumors.

Original languageEnglish (US)
Pages (from-to)750-757
Number of pages8
JournalJournal of the National Cancer Institute
Volume110
Issue number7
DOIs
StatePublished - Jan 1 2018

Fingerprint

Fallopian Tubes
Registries
Carcinoma
Incidence
Population
Neoplasms
Carcinoma in Situ
Confidence Intervals
Pathology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Reported incidence and survival of fallopian tube carcinomas : A population-based analysis from the North American Association of central cancer registries. / Trabert, Britton; Coburn, Sally B.; Mariani, Andrea; Yang, Hannah P.; Rosenberg, Philip S.; Gierach, Gretchen L.; Wentzensen, Nicolas; Cronin, Kathy A.; Sherman, Mark E.

In: Journal of the National Cancer Institute, Vol. 110, No. 7, 01.01.2018, p. 750-757.

Research output: Contribution to journalArticle

Trabert, Britton ; Coburn, Sally B. ; Mariani, Andrea ; Yang, Hannah P. ; Rosenberg, Philip S. ; Gierach, Gretchen L. ; Wentzensen, Nicolas ; Cronin, Kathy A. ; Sherman, Mark E. / Reported incidence and survival of fallopian tube carcinomas : A population-based analysis from the North American Association of central cancer registries. In: Journal of the National Cancer Institute. 2018 ; Vol. 110, No. 7. pp. 750-757.
@article{bbb8fd05359c44fda30def3adb34b972,
title = "Reported incidence and survival of fallopian tube carcinomas: A population-based analysis from the North American Association of central cancer registries",
abstract = "Background: Recognition that serous tubal intraepithelial carcinoma (STIC) may represent the first manifestation of many high-grade cancers that were once considered ovarian primary tumors has led to changes in diagnostic practices that could dramatically increase the reporting of tubal carcinomas in US population-based cancer registries. Further, increased detection of early-stage tubal carcinomas through increased recognition coupled with meticulous pathology processing protocols raises important unanswered questions about the clinical behavior of such lesions, which can only be answered using large data sets. However, rates of tubal carcinomas have not been recently analyzed. Accordingly, we analyzed population-based incidence and survival data for fallopian tube carcinoma in situ (CIS; an imperfect surrogate of STIC), tubal carcinomas, and for comparison, ovarian carcinomas, in the North American Association of Central Cancer Registries (NAACCR) registries. Methods: Total counts, standardized incidence rates, and stage-specific survival were computed using 30 NAACCR registries (1999-2012). Temporal incidence rate patterns were analyzed by joinpoint regression with estimates of annual percentage change (APC). All statistical tests were two-sided. Results: Fallopian tube CIS incidence rates were stable from 1999 to 2002, then increased from 2002 to 2012 (APC = 16.2{\%}, 95{\%} confidence interval [CI] = 10.9{\%} to 21.7{\%}, P <.001). Rates of early- and late-stage tubal carcinomas showed similar patterns, whereas high-grade serous ovarian carcinoma rates were relatively stable. Five-year cause-specific survival was 97.9{\%} (95{\%} CI=93.7{\%} to 99.3{\%}) for tubal CIS and 83.2{\%} (95{\%} CI=77.3{\%} to 87.7{\%}) for early-stage high-grade serous tubal carcinoma. Conclusions: Reporting of tubal CIS and tubal carcinoma have increased in recent years, likely reflecting changes in pathology processing of specimens and diagnosis. Developing standardized reporting for tubal neoplasms is needed to enable analysis of outcomes for these comparatively uncommon but increasingly recognized tumors.",
author = "Britton Trabert and Coburn, {Sally B.} and Andrea Mariani and Yang, {Hannah P.} and Rosenberg, {Philip S.} and Gierach, {Gretchen L.} and Nicolas Wentzensen and Cronin, {Kathy A.} and Sherman, {Mark E.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1093/jnci/djx263",
language = "English (US)",
volume = "110",
pages = "750--757",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Reported incidence and survival of fallopian tube carcinomas

T2 - A population-based analysis from the North American Association of central cancer registries

AU - Trabert, Britton

AU - Coburn, Sally B.

AU - Mariani, Andrea

AU - Yang, Hannah P.

AU - Rosenberg, Philip S.

AU - Gierach, Gretchen L.

AU - Wentzensen, Nicolas

AU - Cronin, Kathy A.

AU - Sherman, Mark E.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Recognition that serous tubal intraepithelial carcinoma (STIC) may represent the first manifestation of many high-grade cancers that were once considered ovarian primary tumors has led to changes in diagnostic practices that could dramatically increase the reporting of tubal carcinomas in US population-based cancer registries. Further, increased detection of early-stage tubal carcinomas through increased recognition coupled with meticulous pathology processing protocols raises important unanswered questions about the clinical behavior of such lesions, which can only be answered using large data sets. However, rates of tubal carcinomas have not been recently analyzed. Accordingly, we analyzed population-based incidence and survival data for fallopian tube carcinoma in situ (CIS; an imperfect surrogate of STIC), tubal carcinomas, and for comparison, ovarian carcinomas, in the North American Association of Central Cancer Registries (NAACCR) registries. Methods: Total counts, standardized incidence rates, and stage-specific survival were computed using 30 NAACCR registries (1999-2012). Temporal incidence rate patterns were analyzed by joinpoint regression with estimates of annual percentage change (APC). All statistical tests were two-sided. Results: Fallopian tube CIS incidence rates were stable from 1999 to 2002, then increased from 2002 to 2012 (APC = 16.2%, 95% confidence interval [CI] = 10.9% to 21.7%, P <.001). Rates of early- and late-stage tubal carcinomas showed similar patterns, whereas high-grade serous ovarian carcinoma rates were relatively stable. Five-year cause-specific survival was 97.9% (95% CI=93.7% to 99.3%) for tubal CIS and 83.2% (95% CI=77.3% to 87.7%) for early-stage high-grade serous tubal carcinoma. Conclusions: Reporting of tubal CIS and tubal carcinoma have increased in recent years, likely reflecting changes in pathology processing of specimens and diagnosis. Developing standardized reporting for tubal neoplasms is needed to enable analysis of outcomes for these comparatively uncommon but increasingly recognized tumors.

AB - Background: Recognition that serous tubal intraepithelial carcinoma (STIC) may represent the first manifestation of many high-grade cancers that were once considered ovarian primary tumors has led to changes in diagnostic practices that could dramatically increase the reporting of tubal carcinomas in US population-based cancer registries. Further, increased detection of early-stage tubal carcinomas through increased recognition coupled with meticulous pathology processing protocols raises important unanswered questions about the clinical behavior of such lesions, which can only be answered using large data sets. However, rates of tubal carcinomas have not been recently analyzed. Accordingly, we analyzed population-based incidence and survival data for fallopian tube carcinoma in situ (CIS; an imperfect surrogate of STIC), tubal carcinomas, and for comparison, ovarian carcinomas, in the North American Association of Central Cancer Registries (NAACCR) registries. Methods: Total counts, standardized incidence rates, and stage-specific survival were computed using 30 NAACCR registries (1999-2012). Temporal incidence rate patterns were analyzed by joinpoint regression with estimates of annual percentage change (APC). All statistical tests were two-sided. Results: Fallopian tube CIS incidence rates were stable from 1999 to 2002, then increased from 2002 to 2012 (APC = 16.2%, 95% confidence interval [CI] = 10.9% to 21.7%, P <.001). Rates of early- and late-stage tubal carcinomas showed similar patterns, whereas high-grade serous ovarian carcinoma rates were relatively stable. Five-year cause-specific survival was 97.9% (95% CI=93.7% to 99.3%) for tubal CIS and 83.2% (95% CI=77.3% to 87.7%) for early-stage high-grade serous tubal carcinoma. Conclusions: Reporting of tubal CIS and tubal carcinoma have increased in recent years, likely reflecting changes in pathology processing of specimens and diagnosis. Developing standardized reporting for tubal neoplasms is needed to enable analysis of outcomes for these comparatively uncommon but increasingly recognized tumors.

UR - http://www.scopus.com/inward/record.url?scp=85055417630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055417630&partnerID=8YFLogxK

U2 - 10.1093/jnci/djx263

DO - 10.1093/jnci/djx263

M3 - Article

C2 - 29281053

AN - SCOPUS:85055417630

VL - 110

SP - 750

EP - 757

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 7

ER -